Evidence map›Paper›PMID 40586900›Full record

ArticleClinical research in cardiology : official journal of the German Cardiac Society2026

Target doses of guideline-directed medical therapeutic agents predicts response to cardiac resynchronization therapy.

Tyler J Kingma, Hossam Albeyoumi, Madhumita Kolluri, Avin Sapowadia, Aryan Mehta, Obada Kholoki, Siddhant Passey, Dorothy Wakefield, Saima Husain

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tyler J KingmaInternal Medicine, University of Connecticut Health, 263 Farmington Avenue, Farmington, CT, 06030-1235, USA. kingma@uchc.edu.ORCID http://orcid.org/0009-0004-0094-9993
Hossam AlbeyoumiInternal Medicine, University of Connecticut Health, 263 Farmington Avenue, Farmington, CT, 06030-1235, USA.
Madhumita KolluriInternal Medicine, University of Connecticut Health, 263 Farmington Avenue, Farmington, CT, 06030-1235, USA.
Avin SapowadiaFrank H. Netter School of Medicine, 370 Bassett Rd, North Haven, CT, USA.
Aryan MehtaInternal Medicine, University of Connecticut Health, 263 Farmington Avenue, Farmington, CT, 06030-1235, USA.
Obada KholokiInternal Medicine, University of Connecticut Health, 263 Farmington Avenue, Farmington, CT, 06030-1235, USA.
Siddhant PasseyInternal Medicine, University of Connecticut Health, 263 Farmington Avenue, Farmington, CT, 06030-1235, USA.
Dorothy WakefieldCardiology Department, St Francis Hospital of New England, 114 Woodland Street, Hartford, CT, USA.
Saima HusainCardiology Department, St Francis Hospital of New England, 114 Woodland Street, Hartford, CT, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe mainstay of therapy in patients with heart failure with reduced ejection fraction (HFrEF) has long been guideline-directed medical therapy (GDMT). This is further complicated by those who have concomitant ventricular dyssynchrony due to conduction abnormalities requiring implantable cardioverter-defibrillators or cardiac resynchronization therapy (CRT). The aim in our study was to investigate the role of GDMT in predicting response to CRT.

methodsWe performed a retrospective chart review of 181 patients at St. Francis Hospital of Trinity Health of New England and UConn John Dempsey Hospital with HFrEF diagnosis who underwent CRT between 01/01/2014 to 01/01/2024. Specifically, individual medications were evaluated as either meeting the target dose or not of GDMT prior to CRT. Then, the effect of achieving target doses was then compared in patients deemed CRT 'responders' and 'non-responders'.

resultsPatients receiving a higher number of optimally dosed GDMT showed a significant trend (p = 0.0277) toward responding to CRT. There was no significant difference between 1 and 0 therapies (OR 1.487; 95% CI, 0.689-3.209) and between 1 and 2-4 (OR 0.427; 95% CI, 0.123-1.487). However, patients receiving 2-4 optimally dosed GDMT were 3.48 times (95% CI, 1.050-11.529) more likely to be a responder when compared to those on 0 optimally dosed therapies.

conclusionsThere is a statistically significant trend toward responding to CRT when patients are on a higher number of optimally dosed GDMT, especially with > 2 therapies. Based on this data, patients should be optimized with as many optimally dosed medications as tolerated for improved outcomes.

Indexed as

Cardiac Resynchronization TherapyCardiovascular AgentsHeart FailurePractice Guidelines as TopicStroke VolumeAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeCardiovascular AgentsCardiac resynchronization therapyCRTGDMTHeart failure

Identifiers

PMID40586900

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.